A pilot study of GE-137 fluorescence imaging to improve the accuracy of surgical excision in patients with breast cancer or oral cancer

Trial Profile

A pilot study of GE-137 fluorescence imaging to improve the accuracy of surgical excision in patients with breast cancer or oral cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs EMI-137 (Primary)
  • Indications Early breast cancer; Orofacial cancer; Squamous cell cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 11 Dec 2015 Accrual to date is 2% according to United Kingdom Clinical Research Network record.
    • 03 Dec 2015 Status changed from not yet recruiting to recruiting, according to United Kingdom Clinical Research Network record.
    • 15 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top